- Stocks
- Healthcare
- NASDAQ: FLXN

Price (delayed)

$9.16

Market cap

$457.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.2

Enterprise value

$589.42M

The EPS is up by 42% year-on-year and by 13% since the previous quarter

The net income is up by 27% year-on-year and by 7% since the previous quarter

FLXN's equity has dropped by 133% since the previous quarter but it is up by 26% year-on-year

Flexion Therapeutics's quick ratio has decreased by 27% YoY and by 14% QoQ

Flexion Therapeutics's gross margin has decreased by 15% YoY and by 4% QoQ

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: https://flexiontherapeutics.com/

What are the main financial stats of FLXN

Market
Valuations
Earnings

Shares outstanding

49.94M

Market cap

$457.47M

Enterprise value

$589.42M

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

5.07

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

6.55

Revenue

$90.01M

EBIT

-$84.47M

EBITDA

-$80.78M

Free cash flow

-$68.44M

Per share
Balance sheet
Liquidity

EPS

-$2.2

Free cash flow per share

-$1.37

Book value per share

-$0.78

Revenue per share

$1.81

TBVPS

$4.62

Total assets

$230.38M

Total liabilities

$269.25M

Debt

$230.65M

Equity

-$38.87M

Working capital

$146.64M

Debt to equity

-5.93

Current ratio

3.53

Quick ratio

3.18

Net debt/EBITDA

-1.63

Margins
Efficiency
Dividend

EBITDA margin

-89.7%

Gross margin

74.4%

Net margin

-117.2%

Operating margin

-92.9%

Return on assets

-41.5%

Return on equity

N/A

Return on invested capital

-27.8%

Return on capital employed

-49%

Return on sales

-93.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Flexion Therapeutics stock price performed over time

Intraday

-1.61%

1 week

-1.51%

1 month

8.4%

1 year

-30.29%

YTD

-20.62%

QTD

2.35%

How have Flexion Therapeutics's revenue and profit performed over time

Revenue

$90.01M

Gross profit

$66.96M

Operating income

-$83.58M

Net income

-$105.46M

Gross margin

74.4%

Net margin

-117.2%

Flexion Therapeutics's operating margin has increased by 41% YoY and by 15% from the previous quarter

FLXN's operating income is up by 36% YoY and by 10% from the previous quarter

The net margin has grown by 33% YoY and by 12% from the previous quarter

The net income is up by 27% year-on-year and by 7% since the previous quarter

What is Flexion Therapeutics's growth rate over time

What is Flexion Therapeutics stock price valuation

P/E

N/A

P/B

N/A

P/S

5.07

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

6.55

The EPS is up by 42% year-on-year and by 13% since the previous quarter

FLXN's equity has dropped by 133% since the previous quarter but it is up by 26% year-on-year

The P/S is 16% below the last 4 quarters average of 6.0

FLXN's revenue is up by 9% YoY and by 5% from the previous quarter

How efficient is Flexion Therapeutics business performance

The return on sales is up by 39% year-on-year and by 14% since the previous quarter

The ROA has grown by 36% YoY and by 10% from the previous quarter

Flexion Therapeutics's ROIC has increased by 33% YoY and by 11% from the previous quarter

What is FLXN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for FLXN.

How did Flexion Therapeutics financials performed over time

FLXN's total assets is 14% smaller than its total liabilities

FLXN's current ratio is down by 31% YoY and by 14% QoQ

Flexion Therapeutics's quick ratio has decreased by 27% YoY and by 14% QoQ

FLXN's equity has dropped by 133% since the previous quarter but it is up by 26% year-on-year

FLXN's debt to equity has soared by 57% QoQ but it is down by 38% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.